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Abstract
Background: Little information is available on the effect of allergen-specific immunotherapy on airway
responsiveness and markers in exhaled air. The aims of this study were to assess the safety of immunotherapy with
purified natural Alt a1 and its effect on airway responsiveness to direct and indirect bronchoconstrictor agents and
markers in exhaled air.
Methods: This was a randomized double-blind trial. Subjects with allergic rhinitis with or without mild/moderate
asthma sensitized to A alternata and who also had a positive skin prick test to Alt a1 were randomized to
treatment with placebo (n = 18) or purified natural Alt a1 (n = 22) subcutaneously for 12 months. Bronchial
responsiveness to adenosine 5′-monophosphate (AMP) and methacholine, exhaled nitric oxide (ENO), exhaled
breath condensate (EBC) pH, and serum Alt a1-specific IgG4 antibodies were measured at baseline and after 6 and
12 months of treatment. Local and systemic adverse events were also registered.
Results: The mean (95% CI) allergen-specific IgG4 value for the active treatment group increased from 0.07 μg/mL
(0.03-0.11) at baseline to 1.21 μg/mL (0.69-1.73, P < 0.001) at 6 months and to 1.62 μg/mL (1.02-2.22, P < 0.001) at
12 months of treatment. In the placebo group, IgG4 value increased nonsignificantly from 0.09 μg/mL (0.06-0.12) at
baseline to 0.13 μg/mL (0.07-0.18) at 6 months and to 0.11 μg/mL (0.07-0.15) at 12 months of treatment. Changes
in the active treatment group were significantly higher than in the placebo group both at 6 months (P < 0.001)
and at 12 months of treatment (P < 0.0001). However, changes in AMP and methacholine responsiveness, ENO
and EBC pH levels were not significantly different between treatment groups. The overall incidence of adverse
events was comparable between the treatment groups.
Conclusion: Although allergen-specific immunotherapy with purified natural Alt a1 is well tolerated and induces an
allergen-specific IgG4 response, treatment is not associated with changes in AMP or methacholine responsiveness or
with significant improvements in markers of inflammation in exhaled air. These findings suggest dissociation
between the immunotherapy-induced increase in IgG4 levels and its effect on airway responsiveness and
inflammation.
Background
Airway inflammation plays a central role in the patho-
genesis of asthma and is associated with an increase in
airway responsiveness to various spasmogens[1]. Clini-
cally and for research purposes, airway responsiveness
is measured by bronchial challenge, usually with
methacholine or histamine[2]; however, adenosine 5′-
monophosphate (AMP) has been introduced as a
bronchoconstrictive stimulus more recently. Whereas
histamine and methacholine act by a direct effect on the
relevant receptors on airway smooth muscle stimulating
airway muscle contraction directly, AMP-induced
bronchoconstriction occurs predominantly indirectly,
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release of histamine and other mediators with subse-
quent smooth muscle contraction[3,4]. It has been sug-
gested that the bronchial responsiveness to inhaled
AMP may reflect changes in airway inflammation
induced by allergen exposure[5,6] or by allergen immu-
notherapy[7] with greater precision and sensitivity than
the response to direct bronchoconstrictor agents.
Increased concentrations of exhaled nitric oxide
(ENO)[8,9] and acidification of exhaled breath conden-
sate (EBC)[10,11] have been demonstrated in asthma. In
addition, both ENO and EBC pH are correlated with the
number of eosinophils in the lower respiratory tract
[11,12]. Therefore, these parameters have been proposed
as markers of airway inflammation and disease severity
in asthma[13,14].
Alternaria alternata is considered one of the most
important aeroallergens in the United States[15,16] and
in Europe[17]. Moreover, sensitization to A alternata
has been associated with severe cases of asthma and
respiratory arrest[17]. One of the major difficulties for
allergen-specific immunotherapy (SIT) with fungal
extracts arises from the variability and complexity of
fungal organism, with the subsequent difference in com-
position and allergenic potency of commercial extracts
[18,19]. Although Aa l t e r n a t acontains several different
allergens, Alt a1 represents by far the most important
with greater than 90% of sensitized individuals having
IgE antibody against this allergen[20]. Therefore, immu-
notherapy with Alt a1 alone may well suffice to improve
manifestations of sensitization to the entire allergen
composition of Aa l t e r n a t a . The mechanism of action
of SIT is not definitively established, but it might be
consequence of treatment-induced changes on the
underlying immunological mechanisms with the subse-
quent beneficial effect on allergen-induced airway
inflammation[21,22]. Thus, the identification of the
effect of SIT on airway responsiveness and inflammation
might represent a relevant support to the efficacy of
treatment in clinical studies. The effect of SIT on airway
responsiveness to direct bronchoconstrictor agents has
been determined in a limited number of controlled stu-
dies, and the results of these investigations have been
inconsistent[23-31]. To the best of our knowledge, how-
ever, only two studies have determined the effect of SIT
on airway responsiveness to indirect bronchoconstrictor
agents such as cold dry air[32] and inhaled AMP[7].
Additionally, little is known about the effect of SIT on
ENO[33,34] and no information is available about the
effect of SIT on EBC pH.
T h ea i m so ft h i sp i l o ts t u d yw e r et od e t e r m i n et h e
safety of SIT with purified natural Alt a1 and to evaluate
its effects on airway responsiveness and inflammatory
markers in exhaled air and EBC in subjects with
respiratory allergy (allergic rhinitis with or without
asthma) sensitized to this allergen. The primary out-
comes were the airway responsiveness to AMP, ENO
values and side effects. Secondary outcomes included
lung function, airway responsiveness to methacholine,
and EBC pH.
Methods
Subjects
Male and nonpregnant female subjects 9 - 60 yrs of age
with allergic rhinitis, with or without mild/moderate
asthma, and skin sensitization to both Aa l t e r n a t aand
Alt a1 (3 μg/mL, Diater Laboratories, Madrid, Spain)
were recruited from the allergy clinic of our institution.
Sensitization was confirmed by skin prick test (weal ≥3
mm) with both A alternata extract and purified natural
Alt a1 (Diater Laboratories S A, Madrid, Spain). Asthma
was identified by the presence of symptoms of wheeze,
breathlessness and cough plus methacholine airway
hyperresponsiveness with a PC20 (provocative concentra-
tion required to produce a 20% fall in FEV1) of less than
8m g / m li ft h eF E V 1/FVC was 70% or greater or an
improvement of the FEV1 from predicted of 15% or
greater after 200 μg of inhaled salbutamol if the FEV1/
FVC was less than 70%. Subjects with allergic rhinitis
were defined as those individuals with a characteristic
history of rhinitis (rhinorrhea, sneezing, obstruction, and
pruritus). All asthmatic subjects were well-controlled for
at least 3 months by treatment with inhaled b2 agonists
on demand or with a daily dose of beclomethasone
dipropionate ≤1000 μg or equivalent. In the 3 months
before the study, patients had asthma symptoms no
more than twice a week, did not wake at night because
of asthma and did not suffer asthma exacerbation. They
had no changes in their dose of inhaled corticosteroids
(ICS) in the last 3 months, and FEV1 al baseline had to
be >70% of predicted. All patients were nonsmokers,
and none had history of chronic bronchitis, emphysema,
or respiratory tract infections during the 4 weeks before
the study. Current smokers and patients with significant
renal, hepatic, or cardiovascular disease were specifically
excluded. The study protocol (DIA-ALE-2004-01) was
approved by the ethics committee of the Hospital Uni-
versitario Dr Peset and the health authorities. Written
informed consent was obtained from each patient or
their parents before participation.
Study design
This was a single-center, randomized, double-blind, pla-
cebo-controlled, parallel-group study. Upon entry of
patients into the study, a detailed history was taken and
physical examination, spirometry, ENO, and bronchial
challenges with methacholine and AMP were carried
out; EBC and blood samples were also obtained.
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separate days with the order of challenge randomized.
Patients were then randomized to receive either active
treatment consisting of increasing doses of purified nat-
ural Alt a1 adsorbed in aluminium hydroxide (Diater
SA, Madrid, Spain) given subcutaneously, followed by
monthly maintenance treatment or placebo (aluminium
hydroxide gel). A maintenance dose of 0.2 μgw a s
achieved in all participants. Extracts for immunotherapy
were reconstituted on the day of administration and sin-
gle-dose vials were used. Patients returned to the labora-
tory after 6 and 12 months of treatment. In each period,
the same determinations performed at baseline were
repeated.
The dose of intranasal or ICS (if used) was maintained
unchanged during the study. Salbutamol metered-dose
inhaler, oral antihistamines and intranasal antihistamines
were used on an “as-needed” basis to control pulmonary
or nasal symptoms, respectively. No other medications
were allowed to be used during the study. Subjects were
asked not to take ICS for 12 hours, salbutamol for at
least 6 hours, oral antihistamines for at least 72 hours
and intranasal antihistamines for at least 24 hours
before each study visit.
Study outcome variables
Inhalation challenge tests
Lung function was measured using a calibrated pneumo-
tachograph (Jaeger MasterScope; Erich Jaeger GmbH;
Würzburg, Germany) according to standardized guide-
lines[35]. Inhalation provocation tests were performed
using a modification of the dosimeter method[36] as
previously reported[37,38]. Methacholine (Provocholine,
Diater SA, Madrid Spain) and AMP (Sigma Chemical; St
Louis, MO, USA) were dissolved freshly in 0.9% saline
solution to produce doubling concentration ranges of
0.095 to 25 mg/ml for methacholine and from 0.39 to
400 mg/ml for AMP. Subjects inhaled the aerosolized
methacholine and AMP solutions (Mefar; Brescia, Italy)
in five respiratory capacity inhalations. The nebulizer
output was 10 μl per breath. The test was interrupted
when a 20% decrease in FEV1 from the post-saline solu-
tion administration value was recorded or when the
highest concentration was administered.
ENO measurement technique
Measurements were performed before spirometry and
challenge tests in accordance with the American Thor-
acic Society/European Respiratory Society recommenda-
tions[39], with a portable device (NIOX-MINO,
Aerocrine AB, Stockholm, Sweden) and defined in parts
per billion (ppb).
Collection of EBC
EBC was collected using the RTube collection system
(Respiratory Research, Inc, Charlottesville, VA) as
previously reported[40]. Aluminium sleeves for RTubes
were kept for at least 1 h in a freezer consistently at
-20°C before use. Subjects breathed normally through
their mouth into the device for 15 min and they were
also instructed to temporarily discontinue collection if
they needed to swallow saliva or cough. Nose clips were
not worn. At the end of collection, the sample was care-
fully removed from the collection system and EBC pH
was determined in a 0.2 ml aliquot immediately after
collection.
Measurement of EBC pH
The pH of the EBC was measured after deaeration with
argon using a calibrated pH meter incorporating a sen-
sor with temperature compensation (model pH 900)
with a Biotrode electrode (Metrohm AG, Herisau, Swit-
zerland), and with an accuracy of ± 0.01 pH. Deaeration
was performed by bubbling argon through the sample
for 8 min[40,41].
Measurement of serum rAlt a1-specific IgG4
Specific IgG4 levels to rAlt a1 were evaluated by means
of the Fluoro enzyme immunoassay (FEIA), following
the instructions of ImmunoCap Specific IgG and IgG4
(Phadia AB, Uppsala, Sweden).
Adverse events
Details of adverse events were collected during the study
on a form that recorded all events, irrespective of sus-
pected relationship to the study medication and of mild,
moderate or serious severity.
Specific immunotherapy
Alternaria alternata extract and nAlt a1 were produced
by Diater (Madrid, Spain). Raw material containing
spores and mycelia of Alternaria Alternata (CBS 103.33)
was purchased from Allergon (Engelholm, Sweden).
Extraction was performed in PBS buffer for 2 hours at
4°C. After centrifugation (4500 g, 30 min) the superna-
tant was filtered, subjected to diafiltration (cut-off 5000
Da) and lyophilized. Alt a1 was purified from Aa l t e r -
nata extract by three chromatographic steps. Briefly, A
alternata extract was reconstituted in starting buffer
(Bis-Tris pH 6.5) and the solution was separated by
anion exchange chromatography (Hitrap Q XL; GE
Healthcare, Uppsala, Sweden). The first peak was col-
lected, desalted and applied to Hitrap SP FF cation
exchange column (GE Healthcare, Uppsala, Sweden)
equilibrated with acetate buffer pH 5.2. The flow-
through fraction was desalted and separated by gel fil-
tration chromatography (Superdex 75 prep grade; GE
Healthcare, Uppsala, Sweden) using ammonium bicarbo-
nate buffer. The fraction containing Alt a1 was lyophi-
lized. A full characterization to Alt a1 was performed
before manufacturing the vaccines (data not shown).
SIT was administered with a cluster schedule that
made it possible to reach the maintenance dose in
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tered in an identical fashion. Maintenance injections
were administered every 4 weeks for 1 year (Table 1).
Skin prick tests
Skin-prick testing was performed with glycerinated sal-
ine (negative control), histamine (1% histamine dihy-
drochloride, positive control), and house dust mites
(Dermatophagoides pteronyssinus and D. farinae),
household pets (cat and dog), pollens (mixed grass,
olive, Parietaria judaica, Artemisia, Platanus orientalis,
Cupresus arizonica and Salsola kali), and moulds (Alter-
naria alternata, Aspergillus fumigatus, Cladosporium
and Penicillium). Furthermore, skin-prick testing was
performed with a standardized extract of purified nat-
ural Alt a1 (3 μg/ml). After 20 min, weal size was
recorded as the long axis and its perpendicular. A skin-
test response was regarded as positive if the weal was ≥3
mm larger in diameter than that of the glycerinated
saline.
Data analysis
An intention-to-treat approach was followed in the ana-
lysis of efficacy data. All patients with a baseline and at
least one postrandomization measurement were
included in the efficacy analysis according to the group
t ow h i c ht h e yw e r er a n d o m i z e d .T h es a f e t yp o p u l a t i o n
comprised all patients who received at least one dose of
SIT or placebo.
To calculate a continuous index of methacholine and
AMP responsiveness, the bronchial responsiveness index
(BRI) was calculated, using the method described by Bur-
rows et al[42] as the percentage decline in FEV1 divided
by the log of the last concentration of agonist, expressed
in mg/dL. All ENO values were log-transformed before
analysis and are presented as geometric means with 95%
confidence intervals (CI). All other numerical variables
are reported as arithmetic means with 95% CI.
The primary outcomes of the study were the BRI to
AMP and ENO concentration. On the basis of previous
data[43], this study had 80% power to detect a
difference of 1.5%/log mg/dL in the BRI to AMP and
>90% power to detect a difference of 7 ppb in the ENO
values between the two groups.
Data were analyzed using a standard statistical soft-
ware package (InStat for Windows version 3.0; Graph-
Pad Software Inc, San Diego, CA, USA). Comparisons of
the baseline characteristics of the two groups were per-
formed by unpaired Student’s t test for continuous data
and by Fisher’s exact tests for categorical data. Compari-
sons of treatment effects of placebo and SIT on BRI to
methacholine, BRI to AMP, FEV1,E N O ,E B Cp Ha n d
serum Alt a1 specific IgG4 were made using two-factor
repeated-measures analysis of variance to analyze the
effect of the two independent variables, treatment and
time, on the outcome variables described previously.
Correlations between variables were calculated with
Pearson correlation coefficient. All comparisons were
two-tailed, and P values less than 0.05 were considered
significant.
Results
Forty-two subjects were enrolled, and 40 were assigned
randomized treatment sets and included in the safety
evaluation. One subject (SIT group) discontinued pre-
maturely before the first visit after randomization due to
an adverse event (local pain in the injection area without
inflammatory signs after the two first doses of SIT), thus
leaving 21 active treatment and 18 placebo subjects for
analysis at 6 months. Fourth patients (SIT group)
declined the previous acceptance for participation after
6 months of treatment for social problems not related
to the treatment. Thus, 35 patients (17 in the actively
treated group and 18 in the placebo group) completed
12 months of treatment. Baseline characteristics were
comparable for the two treatment groups (table 2).
AMP responsiveness
In both groups, changes from baseline in BRI values
after 6 and 12 months of treatment were not significant
(Table 3 and Figure 1). Furthermore, changes in AMP
BRI values were not significantly different between the
SIT and placebo groups, the mean difference being
-0.8%/log mg/dL (-2.5 to 0.9, P = 0.35) and 0.7%/log
mg/dL (-1.3 to 2.6, P = 0.50) after 6 and 12 months of
treatment, respectively.
Exhaled nitric oxide
In both groups, changes from baseline in ENO values
after 6 and 12 months of treatment were not significant
(Table 4 and Figure 2). Furthermore, changes in ENO
were not significantly different between the SIT and pla-
cebo groups, the mean difference being -1.5 ppb (-18.5
to 15.6, P = 0.86) and -6.4 ppb (-26.9 to 14.0, P = 0.53)
after 6 and 12 months of treatment, respectively.
Table 1 Cluster schedule administered during SIT
Day Interval Vial Dose (mL) Allergen dose (mcg/mL)
1 2 0.1 + 0.2 0.0025 + 0.005
8 Weekly 2 0.4 + 0.4 0.01 + 0.01
15 Weekly 3 0.1 + 0.2 0.025 + 0.05
22 Weekly 3 0.4 + 0.4 0.1 + 0.1
37 Fortnightly 3 0.8 0.2
67 Monthly 3 0.8 0.2
97 Monthly 3 0.8 0.2
...* Monthly 3 0.8 0.2
*Monthly doses were administered until the last dose (Vial 3, 0.8 mL)
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In both groups, changes from baseline in FEV1 values
were not significant (Table 3). Furthermore, changes in
FEV1 values were not significantly different between the
SIT and placebo groups, the mean difference being 0.12
L (95% CI, -0.06 to 0.29, P = 0.18) at 6 months and 0.06
L (-0.09 to 0.21, P = 0.91) at 12 months of treatment.
Methacholine responsiveness
In both groups, changes in these values were not signifi-
cant (Table 3 and Figure 1). Furthermore, changes in
methacholine BRI values were not significantly different
between the SIT and placebo groups, the mean differ-
ence being 0.1%/log mg/dL (-2.4 to 2.7, P = 0.92) and
-0.7%/log mg/dL (-3.2 to 1.9, P = 0.61) after 6 and 12
months of treatment, respectively.
Exhaled breath condensate pH
The pH of EBC was not performed in 3 subjects (2 in the
SIT group and 1 in the placebo group) due to technical
problems. Thus EBC pH could be compared in 36 sub-
jects (19 in the SIT group and 17 in the placebo group).
In the SIT group, EBC pH values decreased significantly
(Table 4 and Figure 3) in the evaluation performed after
6 months of treatment (P < 0.05), but not in the final eva-
luation performed after 12 months of treatment. These
changes did not reach significance at any time point in
the placebo group. Furthermore, changes in EBC pH
were not significantly different between the SIT and pla-
cebo groups, the mean difference being 0.30 (-0.28 to
0.88, P = 0.30) and -0.20 (-0.62 to 0.21, P = 0.33) after 6
and 12 months of treatment, respectively.
Alt a1-specific IgG4
Active treatment induced strong IgG4 responses against
the Alt a1 allergen (Table 4). IgG4 concentrations
increased approximately 17-fold after 6 months of treat-
ment and 23-fold after 12 months of treatment. Com-
parison between the groups showed statistically
significant differences at all time points after the com-
mencement of treatment, the mean difference being
1.10 μg/mL (95% CI, 0.63 to 1.57, P < 0.001) and
1.53 μg/mL (95% CI, 0.96 to 2.09, P < 0.0001) after
6 and 12 months of treatment, respectively.
Safety and tolerability
SIT with Alt a1 was well tolerated, with no life-threaten-
ing reactions. The overall incidence of adverse events
was comparable between the treatment groups. There
were 33 local adverse events, 17 and 16 in the active
and placebo groups, respectively. These episodes of
Table 2 Baseline characteristics of the two treatment groups
SIT group (n = 21) Placebo group (n = 18) P
Age*, years 25 (22-29) 22 (18-26) 0.21
Sex (male/femle) 9/12 13/5 0.11
Asthma + rhinitis/rhinitis only 13/8 10/8 0.75
Sensitization to other allergens (yes/no) 17/4 15/3 0.95
ICS treatment (yes/no) 11/10 9/9 0.98
ICS dose* (beclomethasone equivalent), μg/day 392 (268-535) 456 (310-620) 0.51
FEV1*, % predicted 95.4 (89.8-101.0) 99.3 (92.4-106.2) 0.36
FEV1/FVC*, % 78.8 (74.9-82.6) 80.9 (76.6-85.2) 0.44
BRI*, %/log mg/dl
Methacholine 7.2 (4.3-10.1) 7.1 (4.7-9.5) 0.95
AMP 3.6 (2.3-5.0) 3.7 (2.1-5.3) 0.93
ENO**, ppb 38.5 (27.3-54.6) 40.4 827.2-60.1) 0.85
EBC pH* 7.43 (7.15-7.70) 7.50 (7.24-7.77) 0.68
Beclomethasone dipropionate equivalent dose of ICS was calculated on the basis of fluticasone propionate being twice as potent as beclomethasone
dipropionate or budesonide, so that the equivalent fluticasone propionate dose was multiplied 2-fold; *Data are given as means (95% confidence interval);
**Data are given as geometric mean (95% confidence interval). Abbreviations: AMP = adenosine 5’monophosphate; BRI = bronchial responsiveness index; ENO =
exhaled nitric oxide; FEV1= forced expiratory volume in 1 second; FVC = forced vital capacity; EBC = exhaled breath condensate.
Table 3 Changes in FEV1 and in methacholine and AMP
responsiveness in the SIT and placebo groups
Baseline 6 months 12 months
SIT group
FEV1, L 3.31 (2.99-
3.63)
3.32 (3.01-
3.64)
3.31
Methacholine BRI, %/log
mg/dl
7.2 (4.3-10.1) 7.2 (4.8-9.5) 7.4 (5.2-9.5)
AMP BRI, %/log mg/dl 3.6 (2.3-5.0) 4.5 (2.9-6.1) 4.1 (2.7-5.4)
Placebo group
FEV1, L 3.69 (3.21-
4.17)
3.59 (3.15-
4.03)
3.64 (3.20-
4.07)
Methacholine BRI, %/log
mg/dl
7.1 (4.7-9.7) 7.2 (4.7-9.7) 6.6 (4.4-8.9)
AMP BRI, %/log mg/dl 3.7 (2.1-5.3) 3.8 (1.8-5.7) 4.8 (3.0-6.6)
Values are expressed as mean (95% confidence interval). For abbreviations see
Table 2.
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subcutaneous allergen or histamine injection. They were
well tolerated with symptomatic treatment with antihis-
tamines and ice. Thirty-one adverse events were classi-
fied as systemic, with 15 and 16 in the active and
placebo groups, respectively. Most were episodes of rhi-
noconjunctivitis (3 in the active group and 2 in the pla-
cebo group), asthma exacerbation (4 in the active group
and 3 in the placebo group) or common cold (4 in the
active group and 6 in the placebo group). There were 5
episodes of general urticaria or pruritis (2 in the active
group and 3 in the placebo group). All these systemic
adverse events were considered by the investigator as
not related with the study treatment.
Correlations
At baseline, a significant correlation was found between
methacholine and AMP BRI values (r = 0.80, P <
0.0001) as well as between BRI to AMP and ENO (r =
0.38, P = 0.02). There was also a significant correlation
between SIT induced changes in methacholine and
AMP responsiveness (r = 0.68, P = 0.0007 and r = 0.43,
Figure 1 Individual values for the adenosine 5’-monophosphate (AMP) and methacholine bronchial responsiveness index (BRI) in the
specific immunotherapy and placebo groups at baseline and after 6 and 12 months of treatment. Horizontal lines are geometric means.
Changes in AMP BRI values were not significantly different between the SIT and placebo groups (P = 0.35 and P = 0.50 for changes at 6 and 12
months of treatment, respectively). Furthermore, changes in methacholine BRI values were not significantly different between the SIT and
placebo groups (P = 0.92 and P = 0.61 for changes at 6 and 12 months of treatment, respectively).
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respectively). No other correlations were detected.
Discussion
This first clinical study of immunotherapy using a puri-
fied natural Alt a1 (the major A alternata allergen) for
the treatment of allergic rhinitis with or without asthma
demonstrated the good tolerance of the preparation,
together with the induction of strong allergen-specific
IgG4 antibody responses. However, the treatment was
not associated with significant reductions in methacho-
line and AMP responsiveness or with significant
Table 4 Changes in exhaled nitric oxide (ENO), exhaled breath condensate (EBC) pH, and Alt a1-specific IgG4 in serum
Baseline 6 months 12 months
SIT group
ENO, ppb 38.5 (27.3-54.6) 33.4 (25.2-44.4) 37.7 (29.5-48.0)
P NS NS
EBC pH 7.43 (7.15-7.70) 6.91 (6.55-7.28) 7.57 (7.34-7.79)
P < 0.05 NS
Alt a1-specific IgG4, μg/ml 0.07 (0.03-0.11) 1.21 (0.69-1.73) 1.62 (1.02-2.22)
P < 0.001 < 0.001
Placebo group
ENO, ppb 40.4 (27.2-60.1) 32.1 (20.7-49.8) 37.0 (22.9-59.2)
P NS NS
EBC pH 7.50 (7.24-7.77) 7.28 (6.97-7.59) 7.44 (7.21-7.67)
P NS NS
Alt a1-specific IgG4, μg/ml 0.09 (0.06-0.12) 0.13 (0.07-0.18) 0.11 (0.07-0.15)
P NS NS
Values are geometric means (95% confidence interval) for ENO and means (95% confidence interval) for EBC pH and Alt a1-spècific IgG4 values. P values are for
the comparison with baseline values within groups. For abbreviations see Table 2.
Figure 2 Individual values for exhaled nitric oxide (ENO) concentrations in the specific immunotherapy and placebo groups at
baseline and after 6 and 12 months of treatment. Horizontal lines are geometric means. Changes in ENO levels were not significantly
different between the SIT and placebo groups (P = 0.86 and P = 0.53 for changes at 6 and 12 months of treatment, respectively).
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ings suggest that SIT-induced changes in allergen-speci-
fic IgG4 concentrations are not necessarily associated
with improvements in airway responsiveness, ENO or
EBC pH values.
At the time of writing, there has been only one pub-
lished study[7] on the effect of SIT on airway respon-
siveness to AMP. In a group of non-asthmatic subjects
with allergic rhinitis monosensitized to Parietaria
judaica, Polosa et al[7] reported that SIT with Parietaria
pollen extract for two years was associated with a signif-
icant protection against the seasonal deterioration of air-
way responsiveness to AMP, whereas no significant
effect was observed on bronchial hyperresponsiveness to
methacholine. By contrast, our results demonstrated
that AMP responsiveness changed in response to treat-
ment with SIT to a similar extent than did methacholine
responsiveness. Differences in patient characteristics,
study design, allergen administrated for SIT, duration of
treatment and challenge methods between the study by
Polosa et al[7] and the present study preclude a proper
comparison. However, from our results it is evident that
SIT with Alt a1 does not induce significant changes in
AMP responsiveness.
On the other hand, SIT appears to have no effect on
airway responsiveness to methacholine. This confirms
the results of other controlled trials investigating the
effect of SIT administered by subcutaneous injection on
methacholine responsiveness in subjects with respiratory
allergy[7,30,31]. By contrast, other investigations identi-
fied a significant improvement in methacholine respon-
siveness after SIT with house dust mites[23,27] or
pollen allergens[24,25]. Reasons to such discrepancies
are not evident, but might be related to differences in
patients’ characteristics, to diversity in the disease activ-
ity in the subjects studied, to differences in the charac-
teristics of the allergenic extract administered, or to
important differences in the statistical analysis.
It has been hypothesized that SIT results in a devia-
tion in the T lymphocyte response and a modified TH2
response. An increase in T-regulatory cells contributes
to this process, and their production of IL-10 and TGF-
b favors the suppression of IgE production and the
increase in IgG4 antibodies[44,45]. Additionally, it has
been suggested that allergen-specific IgG4 antibodies
have the potential to reduce early responses to allergen
by blocking Fcε-dependent mast cell activation and
release of performed mediators[46]. The results of our
study clearly demonstrate that SIT with purified natural
Alt a1 is associated with a highly significant increase in
allergen-specific IgG4 level. However, the increase in
serum concentrations of allergen-specific IgG4 antibo-
dies in our patients was not associated with a decrease
in the response to AMP, an indirect bronchoconstrictor
Figure 3 Individual values for exhaled breath condensate (EBC) pH in the specific immunotherapy and placebo groups at baseline
and after 6 and 12 months of treatment. Horizontal lines are means. Changes in EBC pH were not significantly different between the SIT and
placebo groups (P = 0.30 and P = 0.33 for changes at 6 and 12 months of treatment, respectively).
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ceptors on mast cells[3,4]. Furthermore, no significant
correlation was detected between SIT-induced modifica-
tions in allergen-specific IgG4 antibodies and AMP
responsiveness. These results suggest that allergen-speci-
fic IgG4 has no potential to downregulate non IgE-
dependent mast cell responses.
In our subjects with respiratory allergy, we did not
detect an affect of SIT on ENO levels. These data are
consistent with those of two previous studies performed
in children[33,34]. However, this is the first study (to
our knowledge) to examine the question of an effect of
SIT on EBC pH. In the group of subjects treated with
SIT, there was a significant decrease in EBC pH, com-
pared with values at baseline, after 6 months of treat-
ment. However, a decrease in EBC pH was also detected
in the placebo group, although it did not reach statisti-
cal significance. Furthermore, differences in modifica-
tions of EBC pH between the two groups were no
significant. Therefore, we believe that the decrease in
EBC pH might be consequence of unidentified technical
or nontechnical factors and that SIT with Alt a1 does
not affect EBC pH values, either positively or negatively.
Because ENO and EBC pH have been proposed as pro-
cedures for the evaluation of airway inflammation
[13,14], our results might be interpreted as an additional
argument for the absence of effect of SIT on airway
inflammation. However, the correlation between ENO
and direct measures of airway inflammation have been
of relatively small magnitude[12], and therefore the pre-
cise mechanism(s) that link(s) nitric oxide with eosino-
philic airway inflammation, and whether elevated ENO
concentrations are caused by enhanced activity of eosi-
nophils or by enhanced diffusion through the airway
wall due to structural damage, remain to be elucidated.
In addition, it must be acknowledged that the interpre-
tation of EBC pH is controversial due to technical fac-
tors[40,47], and there is a debate as to whether orally
collected EBC pH assays reflect acidification of the
lower airways[48].
There were some methodological problems and limita-
tions to this study, which are important to consider.
First, a significant proportion of our patients were taking
inhaled corticosteroids. Given the beneficial effect of
inhaled corticosteroids on pulmonary function, airway
responsiveness, ENO and EBC pH, it could be argued
that the effects of SIT with Alt a1 might be different in
subjects not treated concomitantly with ICS. Therefore,
it would be of interest to repeat this type of study in
steroid-naïve subjects. Second, natural allergen exposure
during each study period was not controlled and we
cannot discard that the lack of effect of SIT with Alt a1
on airway responsiveness or airway inflammation might
be consequence of a low level of natural allergen expo-
sure. Therefore, the resuls of this study might be differ-
ent in subjects sensitized to Aa l t e r n a t atested during a
period of high ambiental allergen exposure. Third, our
patients had mild airway responsiveness. Therefore, the
lack of effect of SIT on methacholine and AMP respon-
siveness might be consequence of the low degree of air-
way responsiveness in our population. Finally, it is
worth noting that most of our patients with A alternata
allergy were also sensitized to other perennial or seaso-
nal allergens. This situation closely emulates what might
happen in the normal clinical setting in which monosen-
sitization to A alternata is exceptionally detected. How-
ever, we acknowledge that the results of this study
might not be applicable to subjects monosensitized to
A alternata.
A favourable safety profile was demonstrated. The
majority of the reactions involved erythema and swelling
in the vicinity of the injection sites consistent with local
allergic reactions or mild trauma caused by the alumi-
num hydroxide suspension. Systemic reactions were
infrequent and mild and occurred with similar preva-
lence in the two groups. Additionally, the fact that all
subjects continued therapy with either the same or
higher doses without further problems indicates that the
preparation is generally well tolerated. By contrast,
although a recent study stated that, in subjects mono-
sensitized to Aa l t e r n a t a ,S I Tw i t has t a n d a r d i z e d
extract was well tolerated[19], it has been reported that
SIT with a standardized whole extract of Alternaria
induces systemic reactions in 19% to 40% of patients
[49,50] and in 2% of injections[50]. Therefore, it appears
that the safety profile of SIT with Alt a1 is superior to
that detected with a conventional standardized extract
of Alternaria.
Conclusions
Although SIT with Alt a1 is well tolerated and induces
an allergen-specific IgG4 response, treatment-induced
changes in airway responsiveness to direct and indirect
bronchoconstrictor agents, ENO and EBC pH values are
no significant. These findings should no necessarily be
interpreted as demonstrative of the lack of clinical effi-
cacy, because immunotherapy-induced changes in air-
way responsiveness or in inflammatory markers have
correlated poorly with clinical responses to treatment
[31,33].
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